Amneal Pharmaceuticals Inc (AMRX)

Überblick Nachrichten Preisverlauf Optionskette Forum Prognose

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile

Amneal Pharmaceuticals Inc

Healthcare (1168)

908-947-3120

400 Crossing Boulevard, 3rd Floor, Bridgewater

@amnealpharma

Nächster Verdiensttermin

Neueste SEC-Einreichungen

AMRX's Discussions on Twitter

Vergleichen Sie AMRX mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
AMRX Amneal Pharmaceuticals Inc	7.485	2.29B	2.68B	-184.45M	229.23M	-0.6805
HLN Haleon Plc Adr	11.07	50.98B	14.35B	1.85B	0	0.4023
ZTS Zoetis Inc	169.71	74.41B	9.29B	2.52B	2.28B	5.57
RDHL Redhill Biopharma Ltd Adr	1.935	4.03M	35.75M	11.57M	-26.25M	-3.8069
TAK Takeda Pharmaceutical Co Adr	14.95	46.23B	30.08B	710.16M	4.45B	0.2182
TEVA Teva Pharmaceutical Industries Ltd Adr	17.54	20.10B	16.54B	-1.64B	749.00M	-1.45

Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-02-24	Hochstufung	JP Morgan	Neutral → Overweight
2024-09-06	Hochstufung	JP Morgan	Underweight → Neutral
2021-04-07	Fortgesetzt	RBC Capital Mkts	Sector Perform
2021-03-08	Hochstufung	Goldman	Sell → Buy
2020-12-14	Hochstufung	Barclays	Equal Weight → Overweight
2020-12-14	Hochstufung	Guggenheim	Neutral → Buy
2020-07-27	Eingeleitet	Goldman	Sell
2020-05-12	Hochstufung	Guggenheim	Sell → Neutral
2019-12-12	Herabstufung	Raymond James	Outperform → Mkt Perform
2019-11-12	Herabstufung	JP Morgan	Neutral → Underweight
2019-11-07	Herabstufung	SVB Leerink	Outperform → Mkt Perform
2019-07-22	Hochstufung	SVB Leerink	Mkt Perform → Outperform
2019-07-11	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2019-07-08	Hochstufung	Piper Jaffray	Neutral → Overweight
2019-06-11	Eingeleitet	Barclays	Equal Weight
2019-05-21	Hochstufung	Raymond James	Mkt Perform → Strong Buy
2019-03-20	Eingeleitet	SunTrust	Buy
2019-03-08	Herabstufung	SVB Leerink	Outperform → Mkt Perform
2018-12-14	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2018-10-16	Herabstufung	SunTrust	Buy → Hold
2018-08-13	Hochstufung	RBC Capital Mkts	Sector Perform → Outperform
2018-07-23	Eingeleitet	Morgan Stanley	Overweight
2018-06-22	Eingeleitet	B. Riley FBR, Inc.	Buy

Alle ansehen

Amneal Pharmaceuticals Inc Aktie (AMRX) Neueste Nachrichten

Finanzdaten der Amneal Pharmaceuticals Inc-Aktie (AMRX)

Amneal Pharmaceuticals Inc (AMRX)

Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile

Vergleichen Sie AMRX mit anderen Aktien

Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades

Amneal Pharmaceuticals Inc Aktie (AMRX) Neueste Nachrichten

Teva, Amneal rated Buy, Viatris Neutral as Goldman Sachs reviews generics space - MSN

AMRX Stock Coverage Initiated with Buy Rating by Goldman Sachs | AMRX Stock News - GuruFocus

Goldman Sachs initiates Amneal Pharmaceuticals stock with neutral rating - Investing.com

Amneal Pharmaceuticals at Jefferies Conference: Strategic Growth Insights By Investing.com - Investing.com Canada

Global Antidote Market to Cross the USD 4 Billion Mark by 2032 | DelveInsight - GlobeNewswire Inc.

Amneal Pharmaceuticals Initiates Nationwide Recall of Contaminated Sulfamethoxazole/Trimethoprim Tablets - Insider Monkey

Amneal Pharmaceuticals (AMRX) Recalls Antibiotic Due to Contamination - GuruFocus

Amneal announces recall of oral antibiotic (AMRX:NASDAQ) - Seeking Alpha

Amneal Recalls Three Lots of Urinary Tract Infection Tablets - marketscreener.com

Amneal Pharmaceuticals (AMRX) Recalls Contaminated Tablets Due to Quality Concerns | AMRX Stock News - GuruFocus

Wall Street Analysts Believe Amneal (AMRX) Could Rally 54.36%: Here's is How to Trade - sharewise

Amneal Recalls Oral Antibiotic Over Contamination Issue - Medical Professionals Reference

Amneal Pharmaceutical LLC Issues a Nationwide Recall of Sulfamethoxazole / Trimethoprim Tablets, USP, 400 mg/80 mg Only, Due to Microbial Contamination - US Recall News

Amneal to Participate at Upcoming Investor Conferences in June - GlobeNewswire

Amneal CEO and CFO Set for Exclusive Presentations at Two Major Healthcare Investor Conferences - Stock Titan

Bank of America Corp DE Has $4.41 Million Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World

FDA approves Amneal’s DHE migraine/cluster headache autoinjector - MSN

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $716,000 Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World

Pharyngitis Treatment Market with Antibiotics and Home - openPR.com

3 Reasons Growth Investors Will Love Amneal (AMRX) - Yahoo Finance

Deutsche Bank AG Has $1.06 Million Stock Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World

Hydroxychloroquine Market to Witness Remarkable Growth with - openPR.com

Insider Sell: Nikita Shah Sells Shares of Amneal Pharmaceuticals Inc (AMRX) - GuruFocus

Migraine Market Enters New Era Following Satsuma Pharmaceuticals' ATZUMI and Amneal Pharmaceuticals' BREKIYA Regulatory Approval | DelveInsight - PR Newswire

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Shares Purchased by BNP Paribas Financial Markets - Defense World

Ameriprise Financial Inc. Sells 49,121 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World

Amneal gets U.S. FDA nod for Brekiya as a migraine treatment - MSN

US FDA approves Amneal's self-administered migraine treatment - Reuters

AMRX Q1 Earnings Call: Miss on Revenue, Margin Expansion, and Product Pipeline Progress - Yahoo Finance

Amneal Gets FDA Nod For Self-Administrable Migraine Injection - MSN

The Manufacturers Life Insurance Company Has $689,000 Stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World

Amneal gets FDA approval for Brekiya to treat migraine and cluster headaches - World Pharmaceutical Frontiers

Amneal’s Brekiya autoinjector approved by FDA for migraines - Investing.com Nigeria

Northern Trust Corp Purchases 156,699 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World

Amneal’s Brekiya autoinjector approved by FDA for migraines By Investing.com - Investing.com South Africa

Amneal Gets FDA Nod For Self-Administrable Migraine Injection By Stocktwits - Investing.com India

FDA Approves Amneal's (AMRX) Brekiya Autoinjector for Migraine R - GuruFocus

US FDA approves Amneal’s self-administered migraine treatment - 1470 & 100.3 WMBD

FDA Greenlights Amneal's (AMRX) Innovative Migraine Treatment | AMRX Stock News - GuruFocus

Amneal Pharmaceuticals' Brekiya Approved by FDA - marketscreener.com

Amneal rises after US FDA greenlights self-administered migraine treatment - TradingView

Amneal Receives U.S. FDA Approval for Brekiya® (dihydroergotamine mesylate) injection for the Acute Treatment of Migraine and Cluster Headaches in Adults - The Manila Times

US FDA approves Amneal's migraine treatment - marketscreener.com

Amneal Receives U.S. FDA Approval for Brekiya® - GlobeNewswire

Breakthrough: First At-Home Injectable Migraine Treatment Gets FDA Green LightWhat Makes It Different - Stock Titan

This Insider Has Just Sold Shares In Amneal Pharmaceuticals - simplywall.st

Amneal Pharmaceuticals (NASDAQ:AMRX) Stock Rating Lowered by StockNews.com - Defense World

Director John Kiely Sells 50,000 Shares of Amneal Pharmaceuticals Inc (AMRX) - GuruFocus

Amneal Proud To Be ‘Made In America’ And Ready To Scale Up Its US Manufacturing - insights.citeline.com

Key Trends Shaping the Future of Filgrastim Biosimilars Market: Amneal Pharmaceuticals' Fylnetra Marks A Ne... - WhaTech

Are Options Traders Betting on a Big Move in Amneal Pharmaceuticals Stock? - MSN

Finanzdaten der Amneal Pharmaceuticals Inc-Aktie (AMRX)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie AMRX